Cargando…

Targeting XPO1 and PAK4 in 8505C Anaplastic Thyroid Cancer Cells: Putative Implications for Overcoming Lenvatinib Therapy Resistance

Lenvatinib is a multitargeted tyrosine kinase inhibitor (TKI) that shows improved median progression-free survival (PFS) in patients with thyroid carcinomas. However, virtually all patients ultimately progress, indicating the need for a better understanding of the mechanisms of resistance. Here, we...

Descripción completa

Detalles Bibliográficos
Autores principales: Khan, Husain Yar, Ge, James, Nagasaka, Misako, Aboukameel, Amro, Mpilla, Gabriel, Muqbil, Irfana, Szlaczky, Mark, Chaker, Mahmoud, Baloglu, Erkan, Landesman, Yosef, Mohammad, Ramzi M., Azmi, Asfar S., Sukari, Ammar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6982268/
https://www.ncbi.nlm.nih.gov/pubmed/31905765
http://dx.doi.org/10.3390/ijms21010237
_version_ 1783491276241371136
author Khan, Husain Yar
Ge, James
Nagasaka, Misako
Aboukameel, Amro
Mpilla, Gabriel
Muqbil, Irfana
Szlaczky, Mark
Chaker, Mahmoud
Baloglu, Erkan
Landesman, Yosef
Mohammad, Ramzi M.
Azmi, Asfar S.
Sukari, Ammar
author_facet Khan, Husain Yar
Ge, James
Nagasaka, Misako
Aboukameel, Amro
Mpilla, Gabriel
Muqbil, Irfana
Szlaczky, Mark
Chaker, Mahmoud
Baloglu, Erkan
Landesman, Yosef
Mohammad, Ramzi M.
Azmi, Asfar S.
Sukari, Ammar
author_sort Khan, Husain Yar
collection PubMed
description Lenvatinib is a multitargeted tyrosine kinase inhibitor (TKI) that shows improved median progression-free survival (PFS) in patients with thyroid carcinomas. However, virtually all patients ultimately progress, indicating the need for a better understanding of the mechanisms of resistance. Here, we examined the molecular profile of anaplastic thyroid cancer cells (8505C) exposed to lenvatinib and found that long-term exposure to lenvatinib caused phenotypic changes. Consistent with change toward mesenchymal morphology, activation of pro-survival signaling, nuclear exporter protein exportin 1 (XPO1) and Rho GTPase effector p21 activated kinases (PAK) was also observed. RNA-seq analysis showed that prolonged lenvatinib treatment caused alterations in numerous cellular pathways and several oncogenes such as CEACAM (carcinoembryonic antigen-related cell adhesion molecule) and NUPR1 (Nuclear protein 1) were also upregulated. Further, we evaluated the impact of XPO1 and PAK4 inhibition in the presence or absence of lenvatinib. Targeted inhibition of XPO1 and PAK4 could sensitize the 8505C cells to lenvatinib. Both XPO1 and PAK4 inhibitors, when combined with lenvatinib, showed superior anti-tumor activity in 8505C sub-cutaneous xenograft. These studies bring forward novel drug combinations to complement lenvatinib for treating anaplastic thyroid cancer. Such combinations may possibly reduce the chances of lenvatinib resistance in thyroid cancer patients.
format Online
Article
Text
id pubmed-6982268
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-69822682020-02-07 Targeting XPO1 and PAK4 in 8505C Anaplastic Thyroid Cancer Cells: Putative Implications for Overcoming Lenvatinib Therapy Resistance Khan, Husain Yar Ge, James Nagasaka, Misako Aboukameel, Amro Mpilla, Gabriel Muqbil, Irfana Szlaczky, Mark Chaker, Mahmoud Baloglu, Erkan Landesman, Yosef Mohammad, Ramzi M. Azmi, Asfar S. Sukari, Ammar Int J Mol Sci Article Lenvatinib is a multitargeted tyrosine kinase inhibitor (TKI) that shows improved median progression-free survival (PFS) in patients with thyroid carcinomas. However, virtually all patients ultimately progress, indicating the need for a better understanding of the mechanisms of resistance. Here, we examined the molecular profile of anaplastic thyroid cancer cells (8505C) exposed to lenvatinib and found that long-term exposure to lenvatinib caused phenotypic changes. Consistent with change toward mesenchymal morphology, activation of pro-survival signaling, nuclear exporter protein exportin 1 (XPO1) and Rho GTPase effector p21 activated kinases (PAK) was also observed. RNA-seq analysis showed that prolonged lenvatinib treatment caused alterations in numerous cellular pathways and several oncogenes such as CEACAM (carcinoembryonic antigen-related cell adhesion molecule) and NUPR1 (Nuclear protein 1) were also upregulated. Further, we evaluated the impact of XPO1 and PAK4 inhibition in the presence or absence of lenvatinib. Targeted inhibition of XPO1 and PAK4 could sensitize the 8505C cells to lenvatinib. Both XPO1 and PAK4 inhibitors, when combined with lenvatinib, showed superior anti-tumor activity in 8505C sub-cutaneous xenograft. These studies bring forward novel drug combinations to complement lenvatinib for treating anaplastic thyroid cancer. Such combinations may possibly reduce the chances of lenvatinib resistance in thyroid cancer patients. MDPI 2019-12-29 /pmc/articles/PMC6982268/ /pubmed/31905765 http://dx.doi.org/10.3390/ijms21010237 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Khan, Husain Yar
Ge, James
Nagasaka, Misako
Aboukameel, Amro
Mpilla, Gabriel
Muqbil, Irfana
Szlaczky, Mark
Chaker, Mahmoud
Baloglu, Erkan
Landesman, Yosef
Mohammad, Ramzi M.
Azmi, Asfar S.
Sukari, Ammar
Targeting XPO1 and PAK4 in 8505C Anaplastic Thyroid Cancer Cells: Putative Implications for Overcoming Lenvatinib Therapy Resistance
title Targeting XPO1 and PAK4 in 8505C Anaplastic Thyroid Cancer Cells: Putative Implications for Overcoming Lenvatinib Therapy Resistance
title_full Targeting XPO1 and PAK4 in 8505C Anaplastic Thyroid Cancer Cells: Putative Implications for Overcoming Lenvatinib Therapy Resistance
title_fullStr Targeting XPO1 and PAK4 in 8505C Anaplastic Thyroid Cancer Cells: Putative Implications for Overcoming Lenvatinib Therapy Resistance
title_full_unstemmed Targeting XPO1 and PAK4 in 8505C Anaplastic Thyroid Cancer Cells: Putative Implications for Overcoming Lenvatinib Therapy Resistance
title_short Targeting XPO1 and PAK4 in 8505C Anaplastic Thyroid Cancer Cells: Putative Implications for Overcoming Lenvatinib Therapy Resistance
title_sort targeting xpo1 and pak4 in 8505c anaplastic thyroid cancer cells: putative implications for overcoming lenvatinib therapy resistance
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6982268/
https://www.ncbi.nlm.nih.gov/pubmed/31905765
http://dx.doi.org/10.3390/ijms21010237
work_keys_str_mv AT khanhusainyar targetingxpo1andpak4in8505canaplasticthyroidcancercellsputativeimplicationsforovercominglenvatinibtherapyresistance
AT gejames targetingxpo1andpak4in8505canaplasticthyroidcancercellsputativeimplicationsforovercominglenvatinibtherapyresistance
AT nagasakamisako targetingxpo1andpak4in8505canaplasticthyroidcancercellsputativeimplicationsforovercominglenvatinibtherapyresistance
AT aboukameelamro targetingxpo1andpak4in8505canaplasticthyroidcancercellsputativeimplicationsforovercominglenvatinibtherapyresistance
AT mpillagabriel targetingxpo1andpak4in8505canaplasticthyroidcancercellsputativeimplicationsforovercominglenvatinibtherapyresistance
AT muqbilirfana targetingxpo1andpak4in8505canaplasticthyroidcancercellsputativeimplicationsforovercominglenvatinibtherapyresistance
AT szlaczkymark targetingxpo1andpak4in8505canaplasticthyroidcancercellsputativeimplicationsforovercominglenvatinibtherapyresistance
AT chakermahmoud targetingxpo1andpak4in8505canaplasticthyroidcancercellsputativeimplicationsforovercominglenvatinibtherapyresistance
AT balogluerkan targetingxpo1andpak4in8505canaplasticthyroidcancercellsputativeimplicationsforovercominglenvatinibtherapyresistance
AT landesmanyosef targetingxpo1andpak4in8505canaplasticthyroidcancercellsputativeimplicationsforovercominglenvatinibtherapyresistance
AT mohammadramzim targetingxpo1andpak4in8505canaplasticthyroidcancercellsputativeimplicationsforovercominglenvatinibtherapyresistance
AT azmiasfars targetingxpo1andpak4in8505canaplasticthyroidcancercellsputativeimplicationsforovercominglenvatinibtherapyresistance
AT sukariammar targetingxpo1andpak4in8505canaplasticthyroidcancercellsputativeimplicationsforovercominglenvatinibtherapyresistance